Af­ter dis­as­trous Gala­pa­gos deal, Gilead finds new rheuma­toid arthri­tis part­ner

Gilead is look­ing for an­oth­er shot at treat­ing rheuma­toid arthri­tis af­ter its mas­sive Gala­pa­gos deal fell flat in the face of an FDA re­jec­tion and, more re­cent­ly, a with­drawn Phase I of an­oth­er as­set for the in­flam­ma­to­ry dis­ease.

The Cal­i­for­nia bio­phar­ma, com­ing off a strong fin­ish to 2022 with an FDA ap­proval and an im­munother­a­py buy­out, is link­ing arms with a Michi­gan up­start al­ready al­lied with Am­gen on au­toim­mune as­sets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER